The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201

Authors

Institutions

Publication Details

Journal
Future Oncology
Published
2025-12-12
DOI
https://doi.org/10.1080/14796694.2025.2595130
Citations
1
Primary Topic
Ovarian cancer diagnosis and treatment
Type
article
Field-Weighted Citation Impact
1.70
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201

Stephanie Lustgarten, Charlie Gourley, Alessandro Davide Santin, Bradley J. Monk et al.
1 citations
Future Oncology
Ovarian cancer diagnosis and treatment
1.70
article

The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201

Stephanie Lustgarten, Charlie Gourley, Alessandro Davide Santin, Bradley J. Monk, David M. O’Malley, Premal H. Thaker, Véronique D’Hondt, Rachel N. Grisham, Andrew R. Clamp, Robert W. Holloway, Manuel Rodrigues, Carol Aghajanian, Kari Lassen Ring, Susana Banerjee, Hagop Youssoufian, Ana Oaknin, Kathleen N. Moore, Emily Prendergast, Toon Van Gorp, Gregg Newman, Nicoletta Colombo, Christine Gennigens, Hye Sook Chon, E. Salinas, Els Van Nieuwenhuysen
article en
1 citations

Abstract

No abstract available for this paper.
Future OncologyVol. 21(30)
Royal Marsden NHS Foundation Trust (GB), Memorial Sloan Kettering Cancer Center (US), Inserm (FR), University of Liège (BE), Washington University in St. Louis (US), Cornell University (US), The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US), Sansum Medical Clinic (US), Edinburgh Cancer Research (GB), Moffitt Cancer Center (US), Yale University (US), Florida Hospital Cancer Institute (US), VIB-KU Leuven Center for Cancer Biology (BE), Florida Cancer Specialists & Research Institute (US), Vall d'Hebron Hospital Universitari (ES), The Christie NHS Foundation Trust (GB), Centre Hospitalier Universitaire de Liège (BE), Institut de Recherche en Cancérologie de Montpellier (FR), Nebraska Cancer Specialists (US), Verastem (United States) (US), Minnesota Oncology (US), Vall d'Hebron Institute of Oncology (ES), University of Oklahoma Health Sciences Center (US), University of Virginia (US), The Ohio State University (US), European Institute of Oncology (IT), University of Milano-Bicocca (IT), Institut Curie (FR), KU Leuven (BE)
Openalex Percentile: Top 11%
Ovarian cancer diagnosis and treatment
1.70
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.